NBNivetha Brathaban

Nivetha Brathaban

*This is an algorithmically generated author record based on publicly available information.

Nivetha Brathaban has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors

    by Quinlan Sievers, Hao Lu, Allison Cool, Stefan Gajewski, Tim Kong, Mark A. Noviski, Sarah Whelan, Yuhan Wang, Lizbeth Mendoza Navarrete, Xiaoli Mi, et al.

    Early-phase clinical trials of Bruton’s tyrosine kinase (BTK) degraders have demonstrated efficacy in patients with BTK inhibitor–resistant chronic lymphocytic leukemia (CLL). How clinical resistance to BTK degraders arises is unknown. In this study, we sequenced serial CLL samples from patients enrolled in phase I trials of zelebrudomide and bexobrutideg and observed recurrent expansion of preexisting BTKA428D mutations at relapse. Unlike previously studied BTK inhibitor resistance mutations, BTKA428D conferred pan-resistance to BTK inhibitors and degraders. In the absence of BTK-directed therapies, however, cells bearing BTKA428D exhibited a competitive disadvantage. A crystal structure of BTKA428D revealed that the mutant aspartate clashes with the adenine ring of adenosine triphosphate and the adenine-mimetic moiety of BTK inhibitors and degraders. Combining BTK degraders with venetoclax mitigated the expansion of BTKA428D. These results provide the molecular basis for clinical resistance to BTK degraders and will inform the development of next-generation BTK degrader therapies. Significance: BTK degraders are a promising new therapy for CLL. We demonstrate that BTKA428D is a recurrent BTK degrader resistance mutation in patients that confers pan-resistance to BTK inhibitors and degraders due to steric clash with their shared, adenine-mimetic moiety. Understanding this mutation can guide the development of next-generation BTK degraders.


  • Open Access

    Bexobrutideg: A Selective, Catalytic Degrader of Bruton’s Tyrosine Kinase Overcomes Inhibitor Resistance and Suppresses Autoantibody-Mediated Disease

    by Mark Noviski, Paul Auger, Danielle Bautista, Nivetha Brathaban, Brandon Bravo, Robert Cass, Ganesh Cherala, Thomas C. Fung, Stefan Gajewski, Dhwani Haria, et al.

    Bruton’s tyrosine kinase (BTK) transduces B-cell receptor (BCR), Toll-like receptor (TLR), and Fc receptor (FcR) signaling, and overactivation of these pathways drives B-cell malignancies and antibody-mediated autoimmune disease. Small molecule inhibitors block the enzymatic functions of BTK, but this inhibition is undermined by resistance mutations, several of which abolish BTK’s kinase activity yet promote oncogenic signaling through BTK scaffolding functions. We report the discovery and characterization of bexobrutideg (NX-5948), a heterobifunctional degrader that recruits cereblon (CRBN) to selectively degrade BTK while sparing molecular glue neosubstrates. We demonstrate that bexobrutideg acts catalytically, degrading thousands of copies of BTK per molecule per hour, and this event-driven pharmacology renders it resilient to mutations that confer resistance to both covalent- and noncovalent-inhibitors. Bexobrutideg is orally bioavailable, driving deep and durable BTK degradation across species. Bexobrutideg demonstrates strong efficacy in wild-type and ibrutinib-resistant lymphoma models and robustly suppresses pathway activation in models of autoimmune disease.


  • Open Access

    Peer Review of “Localized Immune Cascade Programming in Desmoplastic Tumors: In Silico Modeling and Validation Study”

    by Nivetha Brathaban

    This is a peer review report related to "Localized Immune Cascade Programming in Desmoplastic Tumors: In Silico-Validated, Literature-Anchored Systems-Level Model"